Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: Case report and literature review

Journal of Chemotherapy

Volumn 25, Issue 3, 2013, Pages 181-183

  De Hoffer, Laura ^a   Di Biagio, Antonio ^a   Bruzzone, Bianca ^a,b   Sticchi, Laura ^b   Prinapori, Roberta ^a   Gerbaldo, Daniela ^b   Gotta, Cristina ^b   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

HIV 1; HIV RNA decay; Late presenter; Mother to child transmission; Pregnancy; Raltegravir

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CESAREAN SECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOFLUORESCENCE; POLYMERASE CHAIN REACTION; PREGNANCY; VERTICAL TRANSMISSION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELAYED DIAGNOSIS; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, THIRD; PYRROLIDINONES; VIRAL LOAD;

EID: 84878176610     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000066     Document Type: Article

References (13)

1. Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther. 2010;15:677-80.
2. Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R, et al. Raltegravir in pregnancy: a case series presentation. Int J STD AIDS. 2011;22:358-60.
3. Croci L, Trezzi M, Allegri MP, Carli T, Chigiotti S, Riccardi MP, et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol. 2012;68:1231-2.
4. Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother. 2010;65: 2050-2.
5. McKeown DA, Rosenvinge M, Donaghy S, Sharland M, Holt DW, Cormack I, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS. 2010;24:2416-8.
6. Best BM, Capparelli EV, Stek A. Raltegravir pharmacokinetics during pregnancy. Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2010 Sep 12-15; Boston, MA, USA.
7. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Protocol 005 Team: safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-9.
8. Papendorp SG, Van Den Berk GE. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load. AIDS. 2009;23:739.
9. Bruzzone B, Ventura A, Bisio F, Mboungou FA, Miguel LM, Saladini F, et al. Impact of extensive HIV-1 variability on molecular diagnosis in the Congo basin. J Clin Virol. 2010;47:372-5.
10. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Department of Health and Human Services. 2012; 1-235. Available at: http://www.aidsinfo.nih.gov/ContentFiles/lvguidelines/perinatalGL.pdf
11. Connor EM, Mofenson LM. Zidovudine for the reduction of perinatal human immunodeficiency virus transmission: pediatric AIDS Clinical Trials GroupProtocol 076 - results and treatment recommendations. Pediatr Infect Dis J. 1995;14:536- 41.
12. z T cells in a population of HIV-infected individuals. J Virol. 2011;85:10798-805.
13. Antinori A, Cohnen T, Costagliola D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12:61-4.